Back | Next |
home / stock / nspr / nspr message board
Subject | By | Source | When |
---|---|---|---|
The Huge Diluting Pos Scam crashed to $3.41 | Value_Investor | investorshub | 12/11/2021 12:12:49 AM |
This Huge Diluting Pos Scam just crashed to | Value_Investor | investorshub | 12/03/2021 3:33:43 PM |
This Huge Diluting Pos Scam just crashed to | Value_Investor | investorshub | 12/02/2021 10:31:01 PM |
The Huge Diluting Pos Scam just crashed to | Value_Investor | investorshub | 11/19/2021 5:52:47 PM |
Why this Pos Scam could go up to | Value_Investor | investorshub | 11/16/2021 12:52:39 AM |
$NSPR chart | conix | investorshub | 11/15/2021 11:42:44 PM |
Wow, $NSPR hit $4.85 again today in the | Value_Investor | investorshub | 11/03/2021 8:30:07 PM |
Why? It seems $NSPR is heading onto a | Value_Investor | investorshub | 10/30/2021 10:14:29 PM |
Yes, $NSPR is heading onto the Bottom $3.60 | Value_Investor | investorshub | 10/29/2021 8:34:37 PM |
The Pos Scam crashed to $3.80 again a | Value_Investor | investorshub | 10/29/2021 5:31:22 PM |
whytestocks: $NSPR News Article - InspireMD Receives Reimbursement Approval for CGuard(TM) Embolic P | whytestocks | investorshangout | 10/13/2021 1:50:49 PM |
$NSPR 4.44 | TheFinalCD | investorshub | 10/13/2021 1:27:56 PM |
That is a Good News --- New Canada | Value_Investor | investorshub | 09/15/2021 5:27:11 PM |
https://sparknewswire.com/newsfeed/inspiremd-granted-canadian-patent-titled-intr | TheFinalCD | investorshub | 09/15/2021 5:20:00 PM |
IRREVERSIBLE DUMPING | Disquisition | investorshub | 07/27/2021 11:23:26 AM |
INCREDIBLE DUMPING | Disquisition | investorshub | 07/26/2021 3:25:31 PM |
The PUMP AND DUMP is OVER | Disquisition | investorshub | 07/22/2021 2:49:08 PM |
znewcar1: NSPR 30% v14M c5.59 f7,9M H6.82 | znewcar1 | investorshangout | 07/21/2021 8:39:32 PM |
Wait You Should Buy More.lol | iluvkush | investorshub | 07/09/2021 5:21:07 AM |
INSATIABLE DUMPING | Disquisition | investorshub | 07/02/2021 2:35:20 PM |
News, Short Squeeze, Breakout and More Instantly...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...
- Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime has been accepted for presentation at LINC 2...